Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 4997Neoplasms 4192Prostatic Neoplasms 2426Carcinoma, Non-Small-Cell Lung 2261Colorectal Neoplasms 2050Lung Neoplasms 1703Multiple Myeloma 1454Lymphoma 1403Leukemia, Myeloid, Acute 1379Neoplasm Metastasis 1372Melanoma 1269Pancreatic Neoplasms 1200Leukemia 1194Ovarian Neoplasms 1190Lymphoma, Non-Hodgkin 1128Precursor Cell Lymphoblastic Leukemia-Lymphoma 1088Head and Neck Neoplasms 1055Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 896Colonic Neoplasms 893Brain Neoplasms 875Stomach Neoplasms 854Recurrence 848Carcinoma, Hepatocellular 845Glioblastoma 837Lymphoma, Large B-Cell, Diffuse 770Rectal Neoplasms 758Uterine Cervical Neoplasms 725Carcinoma, Renal Cell 704Hodgkin Disease 696

Interventions

brigatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × ALK-positive Advanced NSCLC × Clear all
NCT03535740 2025-07-31

ALTA-2

Takeda

Phase 2 Completed
103 enrolled 23 charts
Thoracic

ALK-positive Advanced NSCLC

NCT03410108 2024-05-08

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

Takeda

Phase 2 Completed
104 enrolled 22 charts
Thoracic

ALK-positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡